BIOCON vs WOCKPHARMA: Stock Comparison

BIOCON vs WOCKHARDTUpdated 4 Sept 26, 4:08 PM ISTNSE & company filings

BIOCON is the larger company by market capitalisation. BIOCON shows a higher dividend yield and lower leverage, while WOCKHARDT shows a lower P/E, a higher ROE and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Metric snapshot

BIOCON leads 5; WOCKPHARMA leads 8 of 13

Not a rating

Interactive comparison

Compare the numbers that shape the decision

Every row uses its own scale. Switch lenses to compare like with like.

BIOCONWOCKPHARMA

Valuation lens

What price are you paying?

Market CapContext only
₹64,740 Cr
₹33,908 Cr
P/E RatioWOCKPHARMA has the lower reading
119.79x
75.68x
P/B RatioBIOCON has the lower reading
1.91x
6.27x
EPSWOCKPHARMA has the higher reading
₹0.87
₹6.58
Book ValueContext only
₹224.71
₹325
Dividend YieldBIOCON has the higher reading
0.13%
0%

✓ marks the usual favourable reading; it is not a recommendation.

Key Differences

Market Cap
BIOCON is the larger company
₹64,740 Cr vs ₹33,908 Cr
P/E Ratio
WOCKPHARMA has a lower P/E
75.68x vs 119.79x
P/B Ratio
BIOCON has a lower P/B
1.91x vs 6.27x
EPS
WOCKPHARMA has higher earnings per share
₹6.58 vs ₹0.87
Dividend Yield
BIOCON has a higher dividend yield
0.13% vs 0%
Revenue Growth (TTM YoY)
WOCKPHARMA has faster revenue growth
26% vs 2.3%
EPS Growth (TTM YoY)
WOCKPHARMA has faster EPS growth
0% vs -72.5%
Qtr Sales Growth
BIOCON has stronger quarterly sales growth
594.32% vs -39.61%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricBIOCONWOCKPHARMA
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricBIOCONWOCKPHARMA
Live Price₹397.4₹2,088.7
Day Change-1.14%7.08%
Volume31.09 L35.58 L
52-Week High₹447.15₹2,422.3
52-Week Low₹337.05₹1,086.7
Distance from 52W High-11.13%-13.77%

Valuation

MetricBIOCONWOCKPHARMA
Market Cap₹64,740 Cr₹33,908 Cr
P/E Ratio119.79x75.68x
P/B Ratio1.91x6.27x
EPS₹0.87₹6.58
Book Value₹224.71₹325
Dividend Yield0.13%0%

Growth

MetricBIOCONWOCKPHARMA
Revenue Growth (TTM YoY)2.3%26%
EPS Growth (TTM YoY)-72.5%0%
Qtr Sales Growth594.32%-39.61%
Qtr Profit Growth162.07%0%

Profitability & Leverage

MetricBIOCONWOCKPHARMA
ROE1.01%10.28%
ROCE2.42%10.37%
Net Margin2.29%3.3%
Operating Margin8.5%28.35%
Debt to Equity0.4x0.57x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricBIOCONWOCKPHARMA
Promoter Holding29.73% 0.17 pp49.08%
FII Holding8.14% 0.62 pp7.22% 0.13 pp
DII Holding23.38% 0.69 pp9.24% 1.72 pp
Public Holding23.75% 0.34 pp34.44% 1.61 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BIOCON and WOCKHARDT.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.